TuisNOTA • FRA
add
Novartis AG
Vorige sluiting
€94,80
Dagwisseling
€96,40 - €96,40
Jaarwisseling
€88,20 - €108,50
Markkapitalisasie
237,05Â mjd USD
Gemiddelde volume
60,00
P/V-verhouding
-
Dividend-opbrengs
-
In die nuus
Finansieel
Inkomstestaat
Inkomste
Netto inkomste
(USD) | Des. 2024info | J/J-verandering |
---|---|---|
Inkomste | 13,56Â mjd | 15,13% |
Bedryfskoste | 6,18Â mjd | 96,66% |
Netto inkomste | 2,82Â mjd | -66,77% |
Netto winsgrens | 20,78 | -71,14% |
Wins per aandeel | 1,98 | 29,41% |
EBITDA | 4,16Â mjd | -41,81% |
Effektiewe belastingkoers | 14,16% | — |
Balansstaat
Totale bates
Totale aanspreeklikheid
(USD) | Des. 2024info | J/J-verandering |
---|---|---|
Kontant en korttermynbeleggings | 13,35Â mjd | -5,13% |
Totale bates | 102,25Â mjd | 2,30% |
Totale aanspreeklikheid | 58,12Â mjd | 9,26% |
Totale ekwiteit | 44,13 mjd | — |
Uitstaande aandele | 1,98 mjd | — |
Prys om te bespreek | 4,25 | — |
Opbrengs op bates | 9,86% | — |
Opbrengs op kapitaal | 13,43% | — |
Kontantvloei
Netto kontantverandering
(USD) | Des. 2024info | J/J-verandering |
---|---|---|
Netto inkomste | 2,82Â mjd | -66,77% |
Kontant van bedrywe | 4,19Â mjd | 64,63% |
Kontant van beleggings | -3,03Â mjd | -72,33% |
Kontant van finansiering | -3,00Â mjd | -393,57% |
Netto kontantverandering | -2,15Â mjd | -317,61% |
Beskikbare kontantvloei | 1,94Â mjd | 143,77% |
Meer oor
Novartis AG is a Swiss multinational pharmaceutical corporation based in Basel, Switzerland. Novartis is one of the largest pharmaceutical companies in the world and was the eighth largest by revenue in 2024.
Novartis manufactures the drugs clozapine, diclofenac, carbamazepine, valsartan, imatinib mesylate, cyclosporine, letrozole, methylphenidate, terbinafine, deferasirox, and others.
Novartis was formed in 1996 by the merger of Ciba-Geigy and Sandoz. It was considered the largest corporate merger in history during that time. The pharmaceutical and agrochemical divisions of both companies formed Novartis as an independent entity. The name Novartis was based on the Latin terms, novae artes.
After the merger, other Ciba-Geigy and Sandoz businesses were sold, or, like Ciba Specialty Chemicals, spun off as independent companies. The Sandoz brand disappeared for three years, but was revived in 2003 when Novartis consolidated its generic drugs businesses into a single subsidiary and named it Sandoz. Wikipedia
Gestig
29 Feb. 1996
Hoofkwartier
Webwerf
Werknemers
75Â 883